Patient characteristics
| ID . | Diagnosis . | Sex . | Age, y . | Previous chemotherapy . | Cytogenetic risk group* . | IPSS . | Best response . |
|---|---|---|---|---|---|---|---|
| 1 | AML-TLD | M | 38 | No | Poor | NA | CR |
| 2 | AML-TLD | M | 78 | No | Poor | NA | NR |
| 3 | AML-TLD | F | 63 | No | Poor | NA | NR |
| 4 | MDS | M | 43 | No | Good | INT-1 | CR |
| 5 | MDS | M | 61 | No | Poor | INT-2 | NR |
| 6 | MDS | M | 79 | No | Good | INT-1 | NR |
| 7 | MDS | F | 64 | No | Good | INT-2 | PR |
| 8 | MDS | M | 84 | No | Good | INT-1 | NR |
| 9 | AML-TLD | F | 55 | No | Good | NA | NR |
| 10 | AML-relapse | M | 67 | No | Poor | NA | PR |
| 11 | CMMoL | F | 61 | No | Good | INT-1 | HI |
| 12 | MDS | M | 66 | No | Intermediate | INT-2 | HI |
| 13 | MDS | M | 74 | No | Intermediate | INT-2 | HI |
| 14 | MDS | F | 61 | No | Good | INT-2 | NR |
| 15 | AML-refractory | F | 35 | Yes | Poor | NA | NR |
| 16 | AML-TLD | M | 83 | No | Good | NA | PR |
| 17 | MDS | M | 74 | No | Good | INT-1 | HI |
| 18 | MDS | M | 75 | No | Good | INT-2 | HI |
| 19 | MDS | M | 52 | No | Intermediate | INT-1 | NR |
| 20 | AML-TLD | M | 70 | Yes | Good | NA | HI |
| 21 | AML-refractory | F | 58 | Yes | Intermediate | NA | NR |
| 22 | MDS | M | 59 | No | Good | INT-1 | PR |
| 23 | CMMoL | M | 65 | No | Poor | NA† | NR |
| 24 | CMMoL | M | 55 | No | Intermediate | INT-1 | NR |
| 25 | MDS | M | 51 | No | Good | INT-2 | NR |
| 26 | AML-TLD | M | 61 | No | Intermediate | NA | NR |
| 27 | CMMoL | M | 69 | No | Intermediate | NA† | NR |
| 28 | AML-TLD | F | 48 | Yes | Good | NA | CR |
| 29 | AML-TLD | F | 65 | No | Intermediate | NA | HI |
| 30 | MDS | M | 78 | Yes | Intermediate | High | NR |
| ID . | Diagnosis . | Sex . | Age, y . | Previous chemotherapy . | Cytogenetic risk group* . | IPSS . | Best response . |
|---|---|---|---|---|---|---|---|
| 1 | AML-TLD | M | 38 | No | Poor | NA | CR |
| 2 | AML-TLD | M | 78 | No | Poor | NA | NR |
| 3 | AML-TLD | F | 63 | No | Poor | NA | NR |
| 4 | MDS | M | 43 | No | Good | INT-1 | CR |
| 5 | MDS | M | 61 | No | Poor | INT-2 | NR |
| 6 | MDS | M | 79 | No | Good | INT-1 | NR |
| 7 | MDS | F | 64 | No | Good | INT-2 | PR |
| 8 | MDS | M | 84 | No | Good | INT-1 | NR |
| 9 | AML-TLD | F | 55 | No | Good | NA | NR |
| 10 | AML-relapse | M | 67 | No | Poor | NA | PR |
| 11 | CMMoL | F | 61 | No | Good | INT-1 | HI |
| 12 | MDS | M | 66 | No | Intermediate | INT-2 | HI |
| 13 | MDS | M | 74 | No | Intermediate | INT-2 | HI |
| 14 | MDS | F | 61 | No | Good | INT-2 | NR |
| 15 | AML-refractory | F | 35 | Yes | Poor | NA | NR |
| 16 | AML-TLD | M | 83 | No | Good | NA | PR |
| 17 | MDS | M | 74 | No | Good | INT-1 | HI |
| 18 | MDS | M | 75 | No | Good | INT-2 | HI |
| 19 | MDS | M | 52 | No | Intermediate | INT-1 | NR |
| 20 | AML-TLD | M | 70 | Yes | Good | NA | HI |
| 21 | AML-refractory | F | 58 | Yes | Intermediate | NA | NR |
| 22 | MDS | M | 59 | No | Good | INT-1 | PR |
| 23 | CMMoL | M | 65 | No | Poor | NA† | NR |
| 24 | CMMoL | M | 55 | No | Intermediate | INT-1 | NR |
| 25 | MDS | M | 51 | No | Good | INT-2 | NR |
| 26 | AML-TLD | M | 61 | No | Intermediate | NA | NR |
| 27 | CMMoL | M | 69 | No | Intermediate | NA† | NR |
| 28 | AML-TLD | F | 48 | Yes | Good | NA | CR |
| 29 | AML-TLD | F | 65 | No | Intermediate | NA | HI |
| 30 | MDS | M | 78 | Yes | Intermediate | High | NR |
AML-TLD indicates AML with trilineage dysplasia; CMMoL, chronic myelomonocytic leukemia; NA, not applicable; INT-1, intermediate-1; INT-2, intermediate-2; and IPSS, International Prognostic Scoring System.
Cytogenetic risk group assigned per IPSS categorization.
CMMoL patients with white blood cell count more than 12 × 109 monocytes/L (121000/μL) were not given an IPSS score.